이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Healius 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Paul Anderson

최고 경영자

AU$234.6k

총 보상

CEO 급여 비율	82.5%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	1.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Paul Anderson 의 보수는 Healius 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	n/a	n/a	-AU$984m
Sep 30 2023	n/a	n/a	-AU$682m
Jun 30 2023	AU$235k	AU$194k	-AU$380m

보상 대 시장: Paul 의 총 보상 ($USD 156.52K ) Australian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.05M ).

보상과 수익: Paul 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Paul Anderson

less than a year

테뉴어

AU$234,618

보상

Mr. Paul D. Anderson serves as Managing Director, Chief Executive Officer since 2024 at Healius Limited and had been Group Chief Financial Officer of Healius Limited since March 1, 2023 and also served as...

리더십 팀

이름	위치	테뉴어	보상	소유권
Paul Anderson	MD, CEO & Director	less than a year	AU$234.62k	데이터 없음
John McKechnie	Advisor	4.9yrs	AU$275.71k	0.028% A$ 287.1k
Jan Van Rooyen	Head & Group Executive of Healius Pathology	1.1yrs	AU$20.68k	데이터 없음
Stephen Humphries	Chief Financial Officer	no data	데이터 없음	데이터 없음
Phil Lucas	Chief Executive of Lumus Imaging	1.5yrs	데이터 없음	데이터 없음
Ian Mcphan	Chief Operating Officer of Healius Pathology	no data	데이터 없음	데이터 없음
Sharon Ng	Head of Group FP&A	no data	데이터 없음	데이터 없음
Arjun Narang	Group Executive of Operations Transformation	1.2yrs	데이터 없음	데이터 없음
Jon Eide	Group Executive of Commercial & Customer	1.3yrs	데이터 없음	데이터 없음
Alejandro Rosales	Head of Digital Strategy & Delivery Office	no data	데이터 없음	데이터 없음
Mary Weaver	Company Secretary	1.3yrs	데이터 없음	데이터 없음
Mark Neeham	Group Executive of Government Relations	9.2yrs	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

경험이 풍부한 관리: HLS 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Paul Anderson	MD, CEO & Director	less than a year	AU$234.62k	데이터 없음
Gordon Davis	Non-executive Director	8.9yrs	AU$181.72k	0.017% A$ 174.9k
Kathryn McKenzie	Interim Non-Executive Independent Chair	3.4yrs	AU$170.70k	0.014% A$ 143.2k
Michael Stanford	Independent Non-Executive Director	less than a year	데이터 없음	0.0045% A$ 46.4k
Ravi Jeyaraj	Director	less than a year	데이터 없음	데이터 없음
Sally Evans	Independent Non-Executive Director	5.9yrs	AU$176.25k	0.011% A$ 114.4k
John Mattick	Non Executive & Independent Director	2.3yrs	AU$157.74k	0.0075% A$ 77.7k
Charlie Taylor	Independent Non-Executive Director	1.3yrs	AU$42.07k	0.016% A$ 166.5k

1.8yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: HLS 의 이사회는 경험(평균 재직 기간 1.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Healius 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

High number of new directors

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Recent updates

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

MD, CEO & Director exercised options to buy AU$2.2m worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Are Investors Undervaluing Healius Limited (ASX:HLS) By 48%?

Healius Reportedly Launches Day Surgery Sale Process

Price target decreased to AU$4.30

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Consensus EPS estimates fall by 13%

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Why Healius Limited (ASX:HLS) Could Be Worth Watching

Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan

Healius Limited's (ASX:HLS) Prospects Need A Boost To Lift Shares

Healius Limited Announces Appointment of John Mattick as Non-Executive Director

Upcoming dividend of AU$0.10 per share

Consensus EPS estimates fall by 11%

Price target decreased to AU$4.94

Healius (ASX:HLS) Is Paying Out A Larger Dividend Than Last Year

First half 2022 earnings: EPS and revenues miss analyst expectations

Healius Limited Announces Ordinary Fully Paid Dividend for the Period of Six Months December 31, 2021, Payable April 15, 2022

Healius Limited to Report First Half, 2022 Results on Feb 23, 2022

Healius Limited (ASX:HLS) acquired Agilex Biolabs Pty Ltd.